Lansoprazole

Generic Name: Lansoprazole

Brand Names: Prevacid, Prevpac

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₄F_₃N_₃O_₂S

CAS Number: 103577-45-3

Unique Ingredient Identifier: 0K5C5T2QPG

Background: Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies caused by excessive acid secretion.

Indication: Lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. It may be used in the maintenance and healing of several gastric conditions including duodenal ulcers, NSAID related gastric ulcers, and erosive esophagitis. Lansoprazole prevents recurrence of gastric ulcers in patients who have a documented history of gastric ulcers who also use NSAIDs chronically. Predictably, it is also useful in the management of hypersecretory conditions including Zollinger-Ellison syndrome. Lansoprazole is effective at eradicating H. pylori when used in conjunction with amoxicillin and clarithromycin (triple therapy) or with amoxicillin alone (dual therapy).

Associated Conditions: Duodenal Ulcer, Erosive Esophagitis, Helicobacter Pylori Infection, Symptomatic Gastroesophageal Reflux Disease (sGERD), Ulcer Healing, Zollinger-Ellison Syndrome, Active Duodenal ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Maintenance of healing Erosive esophagitis

Associated Therapies: -

Clinical Trials

Intraluminal Therapy for Helicobacter Pylori Infection

Phase 4

Completed

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Lansoprazole
Drug: Amoxicillin
Drug: Clarithromycin

First Posted Date: 2017-04-21

Last Posted Date: 2018-05-02

Lead Sponsor: Mackay Memorial Hospital

Target Recruit Count: 100

Registration Number: NCT03124420

Locations: 🇨🇳
Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan, Taipei, Taiwan

Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection

Phase 3

Completed

Conditions: Gastric Ulcer

Interventions: Drug: TAK-438
Drug: Lansoprazole
Drug: Lansoprazole Placebo
Drug: TAK-438 Placebo
Drug: Bismuth-Containing Quadruple Therapy

First Posted Date: 2017-02-10

Last Posted Date: 2021-06-18

Lead Sponsor: Takeda

Target Recruit Count: 234

Registration Number: NCT03050307

Locations: 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
Yijishan hospital of Wan nan Medical college, Wuhu, Anhui, China
🇨🇳
Beijing Chao Yang Hospital, Beijing, Beijing, China

and more 78 locations

Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection

Phase 3

Completed

Conditions: Duodenal Ulcer

Interventions: Drug: TAK-438
Drug: Lansoprazole
Drug: Lansoprazole Placebo
Drug: TAK-438 Placebo
Drug: Bismuth-Containing Quadruple Therapy

First Posted Date: 2017-02-10

Last Posted Date: 2020-06-12

Lead Sponsor: Takeda

Target Recruit Count: 533

Registration Number: NCT03050359

Locations: 🇨🇳
Shiyan Taihe Hospital, Shiyan, Hebei, China
🇨🇳
Jiangxi Nanchang 3rd Hospital, Nanchang, Jiangxi, China
🇰🇷
Korea University Ansan Hospital, Ansan-si, Gyeonggi-do, Korea, Republic of

and more 78 locations

TAK-438 Bismuth Drug Interaction Study

Phase 1

Completed

Conditions: Helicobacter Pylori

Interventions: Drug: Clarithromycin
Drug: Amoxicillin
Drug: Tripotassium bismuth dicitrate
Drug: Lansoprazole
Drug: TAK-438

First Posted Date: 2016-09-08

Last Posted Date: 2019-01-03

Lead Sponsor: Takeda

Target Recruit Count: 30

Registration Number: NCT02892409

Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Erosive Esophagitis

Phase 3

Terminated

Conditions: Erosive Esophagitis

Interventions: Drug: Dexlansoprazole
Drug: Placebo
Drug: Lansoprazole

First Posted Date: 2016-08-19

Last Posted Date: 2019-02-22

Lead Sponsor: Takeda

Target Recruit Count: 37

Registration Number: NCT02873702

Locations: 🇨🇳
Binzhou Medical University Hospital, Binzhou, Shandong, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
Chongqing Three Gorges Central Hospital, Chong Qing, Chong Qing, China

and more 22 locations

Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux Esophagitis

Phase 4

Conditions: Gastroesophageal Reflux Disease

Interventions: Drug: Dexlansoprazole
Drug: Lansoprazole

First Posted Date: 2016-05-03

Last Posted Date: 2016-05-03

Lead Sponsor: National Cheng-Kung University Hospital

Target Recruit Count: 200

Registration Number: NCT02759393

A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis

Phase 4

Completed

Conditions: Gastroesophageal Reflux

Interventions: Drug: Lansoprazole
Drug: Rebamipide-placebo
Drug: Rebamipide

First Posted Date: 2016-04-29

Last Posted Date: 2016-04-29

Lead Sponsor: YongChan Lee

Target Recruit Count: 143

Registration Number: NCT02755753

Locations: 🇰🇷
Soonchunhyang University Bucheon Hospital, Bucheon, Korea, Republic of
🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇨🇳
Yang Shiming, Chongqing, Chongqing, China

and more 2 locations

Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety

Phase 4

Completed

Conditions: Erosive Esophagitis

Interventions: Drug: Vonoprazan
Drug: Lansoprazole

First Posted Date: 2016-02-10

Last Posted Date: 2023-12-13

Lead Sponsor: Takeda

Target Recruit Count: 208

Registration Number: NCT02679508

Locations: 🇯🇵
Tokatsu Tsujinaka Hospital, Abiko, Chiba, Japan
🇯🇵
Hakodate Hospital, Hakodate, Hokkaido, Japan
🇯🇵
Shiga University Of Medical Science Hospital, Otsu, Shiga, Japan

and more 33 locations